CT冠状动脉造影衍生血流储备分数(FFRCT)在英国国家医疗服务体系中的真实世界临床与成本分析
FFRCT使65%患者管理方案改变,取消17%功能学检查及47%诊断性血管造影,并缩短确诊时间;按2020/21拟议收费,狭窄≥50%时CTCA+FFRCT路径每人比常规路径贵44.97英镑。
要点
- CTCA发现≥25%狭窄后行FFRCT可改变约三分之二患者的假设管理方案。
- FFRCT引导下取消部分功能学检查和诊断性血管造影,并缩短确诊时间。
- 成本影响取决于建模的狭窄严重程度,≥50%狭窄时FFRCT路径费用略高。
核心结论
- 在真实NHS环境中,FFRCT引导的管理有潜力优化患者管理、加快诊断路径,并视建模的狭窄严重程度可能具有成本效益。
- FFRCT使65%(64/98)患者的假设管理方案发生改变(p<0.001)。
- FFRCT引导管理的平均确诊时间短于单纯CTCA(28±4天 vs 44±4天;p=0.004)。
研究设计与样本
- 纳入标准为至少一处狭窄≥25%,共105/251例(42%)符合,其中2例不适合FFRCT,FFRCT失败率5%(5/103)。
- 心脏团队在盲法下审阅临床数据与CTCA结果并记录假设管理方案,揭盲FFRCT后重新记录方案。
- 成本分析采用2014-2020年NHS收费,比较FFRCT前后的诊断路径每患者成本。
关键影像表现/征象
- 在42%(105/251)符合条件的病例中,2例不适合FFRCT,FFRCT失败率为5%(5/103)。
诊断标准与关键数值
- FFRCT使假设管理方案改变65%(64/98;p<0.001)。
- FFRCT使17%(17/98)的功能学检查取消、47%(46/98)的诊断性血管造影取消。
- FFRCT引导管理平均确诊时间28±4天,单纯CTCA为44±4天(p=0.004)。
- 按2020/21拟议收费,狭窄≥50%时CTCA+FFRCT诊断路径每患者比无FFRCT常规路径贵44.97英镑。
临床应用与阅片要点
- 对CTCA显示≥25%狭窄的病例,可考虑行FFRCT以辅助功能学评估和管理决策。
- FFRCT结果可能减少不必要的功能学检查和诊断性血管造影,并缩短确诊时间。
- 应用时需注意FFRCT存在约5%的失败率,且成本效益与建模的狭窄严重程度相关。
局限性
- 研究为单中心真实世界分析,样本量有限(FFRCT分析98例)。
- 管理方案为假设性共识而非实际临床结局,成本分析基于NHS收费和特定狭窄阈值建模。
- FFRCT存在5%失败率,可能影响其在部分病例中的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To quantify the real-world clinical and cost impact of computed tomography (CT) coronary angiography (CTCA)-derived fractional flow reserve (FFRCT) in the National Health Service (NHS).
MATERIALS AND METHODS: Consecutive clinical CTCA examinations from September to December 2018 with ≥1 stenosis of ≥25% underwent FFRCT analysis. The Heart Team reviewed clinical data and CTCA findings, blinded to FFRCT values, and documented hypothetical consensus management. FFRCT results were then unblinded and hypothetical consensus management re-recorded. Diagnostic waiting times for management pathways were estimated. A per-patient cost analysis for diagnostic certainty regarding coronary artery disease (CAD) management was performed using 2014-2020 NHS tariffs for pre- and post-FFRCT pathways.
RESULTS: Two hundred and fifty-one CTCAs were performed during the study period. Fifty-seven percent (145/251) had no CAD or stenosis <25%. One study was non-diagnostic. Of the remaining 42% (105/251), two were ineligible for FFRCT and there was a 5% (5/103) failure rate. FFRCT led to a change in hypothetical management in 65% (64/98; p<0.001) patients with a functional imaging test cancelled in 17% (17/98) and a diagnostic angiogram cancelled in 47% (46/98). FFRCT-guided management had a reduced mean time to definitive investigation compared with CTCA alone (28 ± 4 versus 44 ± 4 days; p=0.004). Using the proposed 2020/21 tariff, CTCA + FFRCT for stenosis ≥50% resulted in a diagnostic pathway £44.97 more expensive per patient than usual care without FFRCT.
CONCLUSIONS: In the real-world NHS setting, FFRCT-guided management has the potential to rationalise patient management, accelerate diagnostic pathways, and depending on the stenosis severity modelled, may be cost-effective.
引用
- Graby J, Metters R, Kandan SR, et al. Real-world clinical and cost analysis of CT coronary angiography and CT coronary angiography-derived fractional flow reserve (FFRCT)-guided care in the National Health Service. Clin Radiol. 2021. PMID: 34261595. doi:10.1016/j.crad.2021.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。